← Product Code [LZK](/submissions/SU/subpart-d%E2%80%94prosthetic-devices/LZK) · K961511 # HAPSET HYDROXYLAPATITE BONE GRAFT PLASTER (K961511) _Lifecore Biomedical, Inc. · LZK · Jun 28, 1996 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-d%E2%80%94prosthetic-devices/LZK/K961511 ## Device Facts - **Applicant:** Lifecore Biomedical, Inc. - **Product Code:** [LZK](/submissions/SU/subpart-d%E2%80%94prosthetic-devices/LZK.md) - **Decision Date:** Jun 28, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.3550 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Indications for Use HAPSET is intended for use in facial reconstructive surgery as a paste implant that will set up into a solid block implant of hydroxylapatite and medical grade calcium sulfate. This hydroxylapatite block serves to correct contour defects of facial structures such as chin, mandible, malar region, and maxilla. ## Device Story HAPSET is a bone graft substitute consisting of hydroxylapatite particulate and medical grade calcium sulfate. Supplied as a dry powder with a separate liquid diluent; components are mixed intraoperatively to form a moldable paste. The paste is applied by a surgeon to the facial surgical site (chin, mandible, malar region, maxilla) and molded to the desired contour. Once applied, the material sets into a solid hydroxylapatite/calcium sulfate block. The solid form stabilizes the hydroxylapatite particles, preventing migration—a known issue with loose particulate implants. Used in clinical settings for facial reconstruction and contour defect correction. Benefits include biocompatibility, non-toxicity, and structural stability for aesthetic and functional augmentation. ## Clinical Evidence No clinical trials conducted for this submission. Evidence relies on literature reports dating back to 1985 regarding the successful use of hydroxylapatite for aesthetic and medical augmentation. Safety is supported by historical commercial distribution since 1991 (K910432) with no reported adverse events or toxic symptoms in MDR databases. Bench testing confirms the material is non-toxic, non-irritating, and non-hemolytic. ## Technological Characteristics Composition: Hydroxylapatite particles and medical grade calcium sulfate. Form: Dry powder mixed with diluent to form a moldable paste that sets into a solid block. Biocompatible, non-toxic, non-irritating, and non-hemolytic. No energy source or software components. ## Regulatory Identification A chin prosthesis is a silicone rubber solid device intended to be implanted to augment or reconstruct the chin. ## Reference Devices - Prosthesis, Chin, Internal (Implantech, Interpore, Vitek) - Mesh, Surgical, Polymeric (Davol, Ethicon, Gambro, W.L. Gore and Associates) - Prosthesis, PTFE/Carbon Fiber (Vitek) - Polytetrafluoroethylene - Vitreous Carbon - Materials for Maxillofacial Reconstruction (Biomet, Kimberly-Clark) - Demineralized Bone Graft products (Grafton, Tissue Bank sources) - HAPSET ([K910432](/device/K910432.md)) - HA-500 ([K842163](/device/K842163.md), [K852766](/device/K852766.md)) - CAPSET ([K943186](/device/K943186.md), [K955096](/device/K955096.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} VON 00 00 110 1100 LIFE CORE BIOMEDICAL FAX NO. 0123683411 P. U2 1 of 3 L961511 JUN 28 1996 # LIFECORE ## BIOMEDICAL 510(k) SUMMARY 1.1 Manufacturer's Name: Lifecore Biomedical Inc. 3515 Lyman Blvd. Chaska, MN 55318 (612)368-4300 (612)368-3411 - FAX Contact Person: Lynn Cuperus 1.2 Date Prepared: April 8, 1996 1.3 Device Name: HAPSET hydroxylapatite/calcium sulfate plaster 1.4 Common Name: Prosthesis, Facial augmentation implant 1.5 Classification: Implant for cheek and chin, facial/cranial contour filling and bone augmentation for use with oral-maxillofacial fracture reduction procedures. 1.6 Substantially Equivalent Devices: - Prosthesis, Chin, Internal - Implantech - Interpore - Vitek - Mesh, Surgical, Polymeric - Davol - Ethicon - Gambro - W.L. Gore and Associates - Prosthesis, PTFE/Carbon Fiber - Vitek - Polytetrafluoroethylene - Vitreous - Carbon - Materials - for - Maxillofacial Reconstruction - Biomet - Kimberly-Clark - Demineralized Bone Graft products - Grafton - Tissue Bank sources 3515 LYMAN BOULEVARD • CHASKA, MINNESOTA • 55318-3051 • USA 612-368-4300 FAX: 612-368-3411 PRINTED ON RECYCLED PAPER WITH 093 {1} JUN-00-30 11:00 LIFEGRAE STONEBROOK MA NO. 0123003411 P.03 K961511 2 of 3 ## 1.7 Device Description HAPSET consists of hydroxylapatite particulate which is supplied dry, in a mixing cup with medical grade calcium sulfate. The dry material is packaged with a diluent in a separate syringe that is used to mix with the hydroxylapatite/calcium sulfate. The resulting product is a paste-like plaster that is delivered with the appropriate instruments to the prepared surgical site and molded to the desired contours. ## 1.8 Intended Use: HAPSET is intended for use in facial reconstructive surgery as a paste implant that will set up into a solid block implant of hydroxylapatite and medical grade calcium sulfate. This hydroxylapatite block serves to correct contour defects of facial structures such as chin, mandible, malar region, and maxilla. ## 1.9 Technological Characteristics: HAPSET is manufactured from hydroxylapatite particles and medical grade calcium sulfate. The hydroxylapatite particles are chemically equivalent to the hydroxylapatite blocks commercially distributed for the same intended use. Other substantially equivalent devices with the same intended use are manufactured from materials such as silicone, PTFE, PTFE with carbon fibers, and vitreous carbon. Hydroxylapatite and medical grade calcium sulfate are known to be biocompatible and non-toxic which is an advantage over some of the other materials currently available. ## 1.10 Nonclinical Test: HAPSET has been found to be non-toxic, non-irritating, and non-hemolytic. This is the same or an improvement over the toxicological profiles of the other material available for this intended use. ## 1.11 Clinical Test: Reports in the literature indicate that the use of hydroxylapatite particles for aesthetic and medical augmentation have been successful since at least 1985. Clinicians are reporting that the implanted hydroxylapatite is biocompatible, stable and provides successful augmentation. The only reported drawback of the hydroxylapatite particles has been migration of the particles. HAPSET, in its plaster form, stabilize the particles and lessen the opportunity for particle migration by the setting of the implant into a solid block implant. 094 {2} J THU 12:00 LIFECORE 5.0MEDICAL FAX NO. 5123683411 P.04 K961511 3 of 3 Further, HAPSET has been commercially distributed by Lifecore since 1991, cleared for marketing by 510(k) K910432. No side effects, adverse events or toxic symptoms have been reported to date according to Lifecore and MDR databases. The HA-500 portion of HA is commercially marketed under 510(k) K842163 and K852766. Calcium Sulfate is marketed under the trade name CAPSET and was cleared to market via K943186 and K955096. All of these related devices have been shown in the medical industry to be non-toxic, safe and effective for the intended use on the product labeling. ## 1.12 Conclusions: HAPSET, when used according to labeled directions, provides an implant that is substantially equivalent to hydroxylapatite blocks and other facial implants as noted. It is biocompatible and has demonstrated clinical safety and effectiveness for the same intended use as the current labeling applications listed. HAPSET use is being expanded for indications that include augmentation of the chin or cheek, for correcting of contour defects such as those created during autogenous bone grafting, and fracture reduction. 095 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-d%E2%80%94prosthetic-devices/LZK/K961511](https://fda.innolitics.com/submissions/SU/subpart-d%E2%80%94prosthetic-devices/LZK/K961511) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com